Biotech major, Amgen, Inc. AMGN presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha, at the 2017 American College of Cardiology ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Amgen’s cholesterol drug Repatha proved effective at lowering the risk of heart attacks, strokes and death in patients with heart disease in a recent clinical trial, reports Reuters. When reporting ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Amgen is cutting the list price of its cholesterol drug Repatha by 60% to $5,850 in an unprecedented move to make the drug available to senior citizens. “We’ve got to make sure those who need [Repatha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback